4-甲基哌嗪-1-羧脒 | 45798-01-4

• 物质功能分类: 化学试剂 - 有机试剂 - 亚氨、脒
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-甲基哌嗪-1-羧脒
• 中文别名: 4-甲基哌嗪-1-脒0.5H2SO4；4-甲基哌嗪-1-甲酰亚胺酰胺；4-甲基哌嗪-1-甲脒；4-甲基哌嗪-1-甲酰亚胺酰胺硫酸盐
• 英文名称: 4-methyl piperazine-1-carboximidamide
• 英文别名: 4-methylpiperazine-1-carboximidamide；4-Methyl-1-piperazincarboxamidin；4-methyl-piperazine-1-carboximidic acid amide；(1-methyl-4-piperazino) carboxamidine；1-Guanyl-4-methyl-piperazin
• CAS: 45798-01-4
• 化学式: C₆H₁₄N₄
• mdl: MFCD04116804
• 分子量: 142.204
• InChiKey: JJAQEBBJCVBCKC-UHFFFAOYSA-N

物化性质

• 沸点：
  214.5±50.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  56.4
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4-甲基哌嗪-1-羧脒 在 吡啶 、 sodium ethanolate 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 35.0h， 生成 N-(4-fluorophenyl)-2-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine
  参考文献：
  名称：

  Novel pyrimidoazepine analogs as serotonin 5-HT2A and 5-HT2C receptor ligands for the treatment of obesity

  摘要：

  Obesity is one of the most serious public health problems worldwide in the 21st century. Current therapeutic treatment for obesity is mostly focused on preventive measures involving dietary control and physical exercises in combination with anti-obesity medications. However, most of these anti-obesity medications have little or no effect on weight loss, and some cases have demonstrated fatal side effects. Due to the urgent need for highly potent and selective anti-obesity agents, the serotonin receptors (5-HTR) have been the focus of much interest as a novel therapeutic target. In this report, we have developed pyrimidoazepine analogs targeting the 5-HT2A and 5-HT2C receptors and evaluated their biological activity in vitro and in vivo as novel anti-obesity agents. We were able to identify 6p as the most potent 5-HT2A and 5-HT2C ligand in vitro (IC50 = 3 nM and 2.3 nM, respectively), and this compound also demonstrated the greatest potency in vivo. In an acute obesity model, mice treated with 6p showed significant decrease in body weight gain and food intake over approximately 77-94% compared to a control group. In a chronic obesity model, mice treated with 6p also showed a marked decrease in food intake and body weight gain. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.02.020
• 作为产物：
  描述：

  4-methylpiperazine-1-carboxamidine hydrochloride 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 4-甲基哌嗪-1-羧脒
  参考文献：
  名称：

  �ber N1- und N2-substituierte 2-Amino-5,6-dihydro-4(1H)-pyrimidinone

  摘要：

  DOI：

  10.1007/bf00798460

文献信息

• Synthesis and antitumor activities of a new series of 4,5-dihydro-1H-thiochromeno[4,3-d]pyrimidine derivatives
  作者：DeXiang Guo、YaJing Liu、Ting Li、Nan Wang、Xin Zhai、Chun Hu、Ping Gong

  DOI：10.1007/s11426-011-4477-6

  日期：2012.3

  A new series of 4,5-dihydro-1H-thiochromeno[4,3-d]pyrimidine derivatives have been designed and synthesized. The antitumor activities of the target compounds have been evaluated in vitro against two human cancer cell lines including A549 (human alveolar adenocarcinoma cell) and H460 (human lung cancer) by MTT assay. Most of the target compounds exhibited significant antitumor activities against A549 and H460 cancer cell lines. The most potent compound 4-(benzo[d][1,3]dioxol-5-yl)-8,9-difluoro-2-(4-methylpiperazin-1-yl)-4,5-dihydro-1H-thiochromeno[4,3-d]pyrimidine (CH05) (IC50 = 0.44 μM, 3.07 μM) was 2.0 and 8.4 times more active than gefitinib (IC50 = 0.89 μM, 16.81 μM) against A549 and H460 cell lines, respectively.

  设计并合成了一系列4,5-二氢-1H-硫杂色满并[4,3-d]嘧啶衍生物。通过MTT法，在体外对两种人癌细胞系（包括A549（人肺泡腺癌细胞）和H460（人肺癌细胞））进行了目标化合物的抗肿瘤活性评估。大多数目标化合物对A549和H460癌细胞系表现出显著的抗肿瘤活性。其中最强效的化合物4-(苯并[d][1,3]二氧戊环-5-基)-8,9-二氟-2-(4-甲基哌嗪-1-基)-4,5-二氢-1H-硫杂色满并[4,3-d]嘧啶（CH05）（IC50 = 0.44 μM，3.07 μM）对A549和H460细胞系的活性分别是吉非替尼（IC50 = 0.89 μM，16.81 μM）的2.0倍和8.4倍。
• [EN] (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL) UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT<br/>[FR] DÉRIVÉS DE (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TÉTRAHYDRONAPHTALÉN-1-YL)URÉIDO EN TANT QU'INHIBITEURS DE P38 MAPK ANTI-INFLAMMATOIRES POUR TRAITER DES MALADIES DU TRACTUS RESPIRATOIRE
  申请人：CHIESI FARM SPA

  公开号：WO2018224423A1

  公开（公告）日：2018-12-13

  This invention relates to (4-(([l,2,4]triazolo[4,3-a]pyridine-6-yl) oxy)-1,2,3,4-tetrahydronaphthalen-1-yl)ureido derivatives that are p38 MAPK (mitogen activated protein kinase) inhibitors as antiinflammatory agents for treating diseases of the respiratory tract.

  本发明涉及(4-(([1,2,4]三唑[4,3-a]吡啶-6-基)氧基)-1,2,3,4-四氢萘-1-基)脲衍生物，该衍生物作为抗炎剂用于治疗呼吸道的疾病，是p38 MAPK（丝裂原活化蛋白激酶）的抑制剂。
• FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20140330006A1

  公开（公告）日：2014-11-06

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位间连接和/或修改的3'和/或5'-末端基团的功能修饰寡核苷酸类似物。所公开的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。
• SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS
  申请人：Purdue Pharma L.P.

  公开号：US20150057300A1

  公开（公告）日：2015-02-26

  The present disclosure provides substituted piperidines or pyrrolidines having Formula IA: and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2a , R 2b , R 6 , A, X, m and n are defined as set forth in the specification. In certain embodiments, Compounds of the present disclosure are useful for treating pain. The present disclosure is also directed to the use of Compounds of the present disclosure to treat a disorder responsive to blockade of one or more sodium channels.

  本公开提供具有公式IA的取代哌啶或吡咯烷： 及其药用可接受的盐和溶剂化物，其中R1，R2a，R2b，R6，A，X，m和n按说明书定义。在某些实施方式中，本公开的化合物可用于治疗疼痛。本公开还涉及使用本公开的化合物来治疗对阻断一个或多个钠通道有反应的疾病。
• PYRIDINES AND PYRIMIDINES AND USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20170008882A1

  公开（公告）日：2017-01-12

  The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W 1 , W 2 , W 3 , and R 5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.

  本公开提供了Formula I的吡啶和嘧啶以及其药用可接受的盐和溶剂化合物：其中A、G、W1、W2、W3和R5如规范中所述。本公开还提供了Formula I化合物及其药用可接受的盐和溶剂的用途。在某些实施例中，本公开的化合物对治疗疼痛有用。在另一实施例中，本公开的化合物对治疗对钠通道阻滞有反应的疾病，或缓解该疾病的症状有用。